• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYBoard
  • MYInsights
  • Strategy & Consulting
  • Contact Us
Select Page

Daratumumab regimen extends PFS among certain patients with relapsed or refractory myeloma

by | Dec 15, 2021 | Uncategorized

Source: Healio News The addition of daratumumab to pomalidomide and dexamethasone extended PFS among patients with relapsed or refractory multiple myeloma who were refractory to lenalidomide, according to a study presented at ASH Annual Meeting and Exposition.The...

VIDEO: Early data on novel CAR T-cell targets, combination therapy tops ASH virtual meeting

by | Dec 14, 2021 | Uncategorized

Source: Healio News In this video, Saad Usmani, MD, division chief of plasma cell disorders and director of clinical research in hematologic malignancies at Levine Cancer Institute/Atrium Health, offers insights regarding abstracts on developments in chimeric antigen...

Ninlaro-Darzalex Combo Elicits Favorable Treatment Outcomes, Responses in Newly Diagnosed Multiple Myeloma

by | Dec 13, 2021 | Uncategorized

Source: Cure Today articles Treatment with Ninlaro plus Darzalex and a low dose of the steroid dexamethasone was associated with favorable responses to treatment in non-transplant eligible, intermediate-fit patients with newly diagnosed multiple myeloma. Read...

Novel Treatment Combination Shows Promising Results, Tolerable Side Effects in Multiple Myeloma

by | Dec 12, 2021 | Uncategorized

Source: Cure Today articles Patients with relapsed or refractory multiple myeloma experienced a benefit after receiving Xpovio in combination with Darzalex, Velcade and the steroid dexamethasone. Read More

Isatuximab regimen a possible ‘new standard’ for newly diagnosed multiple myeloma

by | Dec 12, 2021 | Uncategorized

Source: Healio News The addition of isatuximab to a standard three-drug induction regimen improved outcomes for certain patients with multiple myeloma, according to randomized phase 3 study results presented at ASH Annual Meeting and Exposition.Half of patients with...

COVID-19 vaccination may be less effective for patients with multiple myeloma

by | Dec 12, 2021 | Uncategorized

Source: Healio News Although vaccination is an effective strategy for COVID-19 prevention, its effectiveness may be reduced in patients with multiple myeloma, likely because of immunosuppression due to the disease process and related therapy.Researchers presented the...
« Older Entries
Next Entries »

Recent Content

  • A systematic epidemiological trends analysis study in global burden of multiple myeloma and 29 years forecast
  • Talquetamab and Teclistamab Achieve Deep, Durable Responses in Patients With Relapsed, Refractory Multiple Myeloma
  • Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the MAIA study
  • Fixed-Dose Subcutaneous Sarclisa Combo is Non-Inferior to IV Sarclisa in R/R Myeloma
  • Whole genome sequencing and the genetics of extramedullary disease in multiple myeloma
  • Tunneling nanotubes between bone marrow stromal cells support transmitophagy and resistance to apoptosis in myeloma
  • IVIG Supplementation Reduces Infection Risk in Patients With Multiple Myeloma Receiving Teclistamab
  • Combination induces durable responses in advanced multiple myeloma
  • Patient-reported outcome domains in multiple myeloma randomized controlled trials and association with survival outcomes
  • Peroxiredoxin 6 maintains mitochondrial homeostasis and promotes tumor progression through ROS/JNK/p38 MAPK signaling pathway in multiple myeloma
  • Facebook
  • X
  • Instagram
©2016-2024 MYELOMA360
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT